Core Insights - Alpha Cognition reported a total revenue of $2.8 million for Q4 2025, with $2.5 million coming from net product sales of ZUNVEYL, and a full-year revenue of $10.2 million, including $6.8 million in net product sales [2][19] - The company emphasized strong adoption of ZUNVEYL in long-term care settings, with a 62% quarter-over-quarter increase in bottles dispensed and 82% of homes ordering in Q4 being repeat customers [6][4] - Management highlighted the importance of payer access, announcing a second national PBM contract, which is expected to enhance market access and reduce prior authorization hurdles [8][9] Sales and Market Performance - In Q4 2025, Alpha Cognition dispensed 4,941 bottles of ZUNVEYL, marking December as the strongest month since the product's launch [1][6] - The company recorded 3,681 healthcare provider calls in Q4, with approximately 865 prescribers writing orders, of which 69% were repeat writers [6][4] - Management described Q4 as an "inflection point" for ZUNVEYL's launch in long-term care, indicating a significant increase in demand [6][3] Financial Overview - Alpha Cognition ended 2025 with approximately $66 million in cash and no debt, providing a financial runway into 2027 [5][20] - The company reported an operating loss of $7.9 million for Q4 2025, compared to $2.7 million in Q4 2024, and a full-year operating loss of $22.7 million [19][20] - Operating expenses for Q4 2025 were $10.7 million, with a significant increase attributed to higher SG&A costs related to commercialization efforts [18][20] Research and Development - Alpha Cognition plans to initiate three real-world studies in 2026, focusing on long-term care and outpatient settings, aimed at evaluating the impact of ZUNVEYL on polypharmacy and behavioral outcomes [12][17] - The company is also developing a sublingual formulation of ZUNVEYL, with plans for a comparative pharmacokinetic study in Q2 2026 [14][15] - Management anticipates that the sublingual formulation could address swallowing difficulties in long-term care patients and plans to engage with the FDA regarding its regulatory path [15][14] Strategic Priorities - For 2026, Alpha Cognition's priorities include enhancing sales execution, improving payer coverage, completing clinical studies on time, advancing the R&D pipeline, and managing expenses to achieve operating profitability by 2027 [21][20] - The company expects continued sequential growth in ZUNVEYL sales throughout 2026 as physician awareness and payer access improve [20][21]
Alpha Cognition Q4 Earnings Call Highlights